Name: Latest research reports of Lupin Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Lupin Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Lupin Ltd.

NSE: LUPIN | BSE: 500257 | ISIN: INE326A01037 | Industry: Pharmaceuticals
| Mid-range Performer

2327.4000 30.70 (1.34%)

NSE Mar 24, 2026 14:55 PM

Near 52W High of ₹2377.60

Volume: 1.1M

Lupin Ltd.

15 Feb 2026

2327.40

1.34%

Lupin (BUY): Multiple growth levers for multiple years

Buy: Lupin Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA /APAT reported 8.2%/13.1%/25% above our estimates. EBITDA Margin reported 130 bps above our estimates

Lupin Ltd. has an average target of 2392.73 from 11 brokers.